Showing results (71-80 of 110) with videos related to

Sort By:
Pageof 11
Blood|June 27, 2023
Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trialMorie A Gertz, Adam D Cohen, Raymond L Comenzo, et al.
Bone Marrow Transplantation|June 24, 2021
Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myelomaChristopher Lemieux, Lori S Muffly, David J Iberri, et al.
Bone Marrow Transplantation|April 7, 2021
Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world dataTalha Badar, Aniko Szabo, Mark Litzow, et al.
Blood Advances|April 12, 2024
Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALLYaqi Zhao, A Douglas Laird, Kathryn G Roberts, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 16, 2020
Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab OzogamicinTalha Badar, Aniko Szabo, Martha Wadleigh, et al.
Leukemia|February 5, 2025
Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myelomaGayathri Ravi, Shambavi Richard, Shaji Kumar, et al.
Blood Advances|May 27, 2020
Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomabTalha Badar, Aniko Szabo, Anjali Advani, et al.
The New England Journal of Medicine|May 3, 2019
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple MyelomaNoopur Raje, Jesus Berdeja, Yi Lin, et al.
Nature Medicine|August 17, 2023
Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trialYi Lin, Noopur S Raje, Jesús G Berdeja, et al.
Blood Advances|August 23, 2021
Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemiaLori Muffly, Vandana Sundaram, Connie Chen, et al.
Pageof 11